加载中
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
常规交易时段
US$7.525
−US$0.725 · -8.79%
盘中时间采用ET。市场数据可能有所延迟。
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
日内区间
当前US$7.525
52周区间
当前US$7.525
盘中时间采用ET。市场数据可能有所延迟。
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
日内区间
当前US$7.525
52周区间
当前US$7.525
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 3091.4万 USD | 1000万 USD | — | 259.6万 USD | 205.3万 USD |
| 销货成本 | 529.8万 USD | — | — | — | — |
| 毛利 | 2561.6万 USD | 1000万 USD | — | 259.6万 USD | 205.3万 USD |
| 研究与开发 | 1.15亿 USD | 8133.4万 USD | 6135.6万 USD | 5055.8万 USD | 3934.7万 USD |
| 销售、一般及管理费用 | 8114.6万 USD | 4362.2万 USD | 3072.8万 USD | 2497.5万 USD | 2411.5万 USD |
| 营业费用 | 1.96亿 USD | 1.25亿 USD | 9208.4万 USD | 7553.3万 USD | 6346.2万 USD |
| 利息收入 | 406.8万 USD | 414.9万 USD | 621.4万 USD | 121.5万 USD | 18.1万 USD |
| 利息支出 | 113.8万 USD | 456.2万 USD | 413.9万 USD | 213.7万 USD | 997.2万 USD |
| 折旧和摊销 | 72.8万 USD | 2.6万 USD | 6.2万 USD | 11.8万 USD | 7.2万 USD |
| 营业利润 | −1.7亿 USD | −1.15亿 USD | −9208.4万 USD | −7293.7万 USD | −6140.9万 USD |
| 净利润 | −2.09亿 USD | −1.31亿 USD | −8736.7万 USD | −7381.2万 USD | −7120万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$14.43
上涨空间 91.76%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年6月1日 | 1:12 | — | — |
已生效 2023年6月1日
1:12
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2030.23万0.00%2.3万亿 USD0.03%US$381.62+0.01%
State Street SPDR S&P Biotech ETFXBI1933.53万0.19%103.03亿 USD0.35%US$147.41-2.64%
iShares Russell 2000 ETFIWM1747.82万0.02%787.4亿 USD0.19%US$277.06-0.30%
Vanguard Extended Market ETFVXF692.4万0.01%954亿 USD0.05%US$232.62-0.39%
Fidelity Enhanced Small Cap ETFFESM687.62万0.10%64.1亿 USD0.28%US$45.165-0.17%
iShares Russell 2000 Growth ETFIWO632.82万0.05%139.17亿 USD0.24%US$351.64-0.59%
Virtus Biotech ETFBBP339.16万2.62%1.31亿 USD0.34%US$100.91-2.62%
Vanguard Russell 2000 ETFVTWO331.43万0.02%180亿 USD0.06%US$111.91-0.33%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOVirtus Biotech ETFBBPVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
